Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. / Alban, Tyler J; Alvarado, Alvaro G; Sorensen, Mia D; Bayik, Defne; Volovetz, Josephine; Serbinowski, Emily; Mulkearns-Hubert, Erin E; Sinyuk, Maksim; Hale, James S; Onzi, Giovana R; McGraw, Mary; Huang, Pengjing; Grabowski, Matthew M; Wathen, Connor A; Ahluwalia, Manmeet S; Radivoyevitch, Tomas; Kornblum, Harley I; Kristensen, Bjarne W; Vogelbaum, Michael A; Lathia, Justin D.

In: JCI Insight, Vol. 3, No. 21, 02.11.2018.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Alban, TJ, Alvarado, AG, Sorensen, MD, Bayik, D, Volovetz, J, Serbinowski, E, Mulkearns-Hubert, EE, Sinyuk, M, Hale, JS, Onzi, GR, McGraw, M, Huang, P, Grabowski, MM, Wathen, CA, Ahluwalia, MS, Radivoyevitch, T, Kornblum, HI, Kristensen, BW, Vogelbaum, MA & Lathia, JD 2018, 'Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis', JCI Insight, vol. 3, no. 21. https://doi.org/10.1172/jci.insight.122264

APA

Alban, T. J., Alvarado, A. G., Sorensen, M. D., Bayik, D., Volovetz, J., Serbinowski, E., Mulkearns-Hubert, E. E., Sinyuk, M., Hale, J. S., Onzi, G. R., McGraw, M., Huang, P., Grabowski, M. M., Wathen, C. A., Ahluwalia, M. S., Radivoyevitch, T., Kornblum, H. I., Kristensen, B. W., Vogelbaum, M. A., & Lathia, J. D. (2018). Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight, 3(21). https://doi.org/10.1172/jci.insight.122264

Vancouver

Alban TJ, Alvarado AG, Sorensen MD, Bayik D, Volovetz J, Serbinowski E et al. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight. 2018 Nov 2;3(21). https://doi.org/10.1172/jci.insight.122264

Author

Alban, Tyler J ; Alvarado, Alvaro G ; Sorensen, Mia D ; Bayik, Defne ; Volovetz, Josephine ; Serbinowski, Emily ; Mulkearns-Hubert, Erin E ; Sinyuk, Maksim ; Hale, James S ; Onzi, Giovana R ; McGraw, Mary ; Huang, Pengjing ; Grabowski, Matthew M ; Wathen, Connor A ; Ahluwalia, Manmeet S ; Radivoyevitch, Tomas ; Kornblum, Harley I ; Kristensen, Bjarne W ; Vogelbaum, Michael A ; Lathia, Justin D. / Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. In: JCI Insight. 2018 ; Vol. 3, No. 21.

Bibtex

@article{8ce319433c534aebb93bfa2f6d8785bb,
title = "Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis",
abstract = "Glioblastoma (GBM) remains uniformly lethal, and despite a large accumulation of immune cells in the microenvironment, there is limited antitumor immune response. To overcome these challenges, a comprehensive understanding of GBM systemic immune response during disease progression is required. Here, we integrated multiparameter flow cytometry and mass cytometry TOF (CyTOF) analysis of patient blood to determine changes in the immune system among tumor types and over disease progression. Utilizing flow cytometry analysis in a cohort of 259 patients ranging from benign to malignant primary and metastatic brain tumors, we found that GBM patients had a significant elevation in myeloid-derived suppressor cells (MDSCs) in peripheral blood but not immunosuppressive Tregs. In GBM patient tissue, we found that increased MDSC levels in recurrent GBM portended poor prognosis. CyTOF analysis of peripheral blood from newly diagnosed GBM patients revealed that reduced MDSCs over time were accompanied by a concomitant increase in DCs. GBM patients with extended survival also had reduced MDSCs, similar to the levels of low-grade glioma (LGG) patients. Our findings provide a rationale for developing strategies to target MDSCs, which are elevated in GBM patients and predict poor prognosis.",
author = "Alban, {Tyler J} and Alvarado, {Alvaro G} and Sorensen, {Mia D} and Defne Bayik and Josephine Volovetz and Emily Serbinowski and Mulkearns-Hubert, {Erin E} and Maksim Sinyuk and Hale, {James S} and Onzi, {Giovana R} and Mary McGraw and Pengjing Huang and Grabowski, {Matthew M} and Wathen, {Connor A} and Ahluwalia, {Manmeet S} and Tomas Radivoyevitch and Kornblum, {Harley I} and Kristensen, {Bjarne W} and Vogelbaum, {Michael A} and Lathia, {Justin D}",
year = "2018",
month = nov,
day = "2",
doi = "10.1172/jci.insight.122264",
language = "English",
volume = "3",
journal = "JCI Insight",
issn = "2379-3708",
publisher = "American Society for Clinical Investigation",
number = "21",

}

RIS

TY - JOUR

T1 - Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis

AU - Alban, Tyler J

AU - Alvarado, Alvaro G

AU - Sorensen, Mia D

AU - Bayik, Defne

AU - Volovetz, Josephine

AU - Serbinowski, Emily

AU - Mulkearns-Hubert, Erin E

AU - Sinyuk, Maksim

AU - Hale, James S

AU - Onzi, Giovana R

AU - McGraw, Mary

AU - Huang, Pengjing

AU - Grabowski, Matthew M

AU - Wathen, Connor A

AU - Ahluwalia, Manmeet S

AU - Radivoyevitch, Tomas

AU - Kornblum, Harley I

AU - Kristensen, Bjarne W

AU - Vogelbaum, Michael A

AU - Lathia, Justin D

PY - 2018/11/2

Y1 - 2018/11/2

N2 - Glioblastoma (GBM) remains uniformly lethal, and despite a large accumulation of immune cells in the microenvironment, there is limited antitumor immune response. To overcome these challenges, a comprehensive understanding of GBM systemic immune response during disease progression is required. Here, we integrated multiparameter flow cytometry and mass cytometry TOF (CyTOF) analysis of patient blood to determine changes in the immune system among tumor types and over disease progression. Utilizing flow cytometry analysis in a cohort of 259 patients ranging from benign to malignant primary and metastatic brain tumors, we found that GBM patients had a significant elevation in myeloid-derived suppressor cells (MDSCs) in peripheral blood but not immunosuppressive Tregs. In GBM patient tissue, we found that increased MDSC levels in recurrent GBM portended poor prognosis. CyTOF analysis of peripheral blood from newly diagnosed GBM patients revealed that reduced MDSCs over time were accompanied by a concomitant increase in DCs. GBM patients with extended survival also had reduced MDSCs, similar to the levels of low-grade glioma (LGG) patients. Our findings provide a rationale for developing strategies to target MDSCs, which are elevated in GBM patients and predict poor prognosis.

AB - Glioblastoma (GBM) remains uniformly lethal, and despite a large accumulation of immune cells in the microenvironment, there is limited antitumor immune response. To overcome these challenges, a comprehensive understanding of GBM systemic immune response during disease progression is required. Here, we integrated multiparameter flow cytometry and mass cytometry TOF (CyTOF) analysis of patient blood to determine changes in the immune system among tumor types and over disease progression. Utilizing flow cytometry analysis in a cohort of 259 patients ranging from benign to malignant primary and metastatic brain tumors, we found that GBM patients had a significant elevation in myeloid-derived suppressor cells (MDSCs) in peripheral blood but not immunosuppressive Tregs. In GBM patient tissue, we found that increased MDSC levels in recurrent GBM portended poor prognosis. CyTOF analysis of peripheral blood from newly diagnosed GBM patients revealed that reduced MDSCs over time were accompanied by a concomitant increase in DCs. GBM patients with extended survival also had reduced MDSCs, similar to the levels of low-grade glioma (LGG) patients. Our findings provide a rationale for developing strategies to target MDSCs, which are elevated in GBM patients and predict poor prognosis.

U2 - 10.1172/jci.insight.122264

DO - 10.1172/jci.insight.122264

M3 - Journal article

C2 - 30385717

VL - 3

JO - JCI Insight

JF - JCI Insight

SN - 2379-3708

IS - 21

ER -

ID: 364504791